News & Events

Latest Cluster News

FEED Trial aims to help Patients with Pancreatic Cancer

Does getting more support with nutrition and physical activity make it easier for patients to maintain weight and feel stronger while having treatment? The FEED Trial at St. Vincent's University Cancer Centre aims to support pancreatic cancer patients undergoing chemotherapy. This research measures the effectiveness of extra nutrition and physical activity in helping these patients stay stronger, maintain weight, and improve energy throughout the duration of their treatment.

Image related to Movember for Men's Health Day

19Nov

Men’s Health Day 2025: Updates on Prostate Cancer Research and Trials

To celebrate Men’s Health Day, we are highlighting three important prostate cancer studies that are helping Ireland improve early detection, treatment, and overall care for men with prostate cancer: PRAISE EU, IPCOR, and PEACE 6.
PRAISE EU is a Europe-wide pilot programme aimed at improving prostate cancer screening.
The Irish Prostate Cancer Outcomes Research (IPCOR) registry, now in its second phase, collects long-term clinical information from men referred for prostate biopsy across multiple hospitals in Ireland, and electronic questionnaires about their health, supportive care needs, and financial concerns before treatment and annually afterward.
PEACE 6 is a clinical trial for men with advanced prostate cancer that tracks cancer progression, side effects, and quality of life over time, helping doctors find safer and more effective treatments for men with advanced prostate cancer.

11Nov

Dr. Oonagh Griffin: Specialist Dietitian and Researcher Focused on Pancreatic Cancer

Meet our team! We are showcasing Dr. Oonagh Griffin, Specialist Dietitian and Researcher focused on pancreatic cancer. Dr. Griffin is a Senior Pancreatic Cancer Dietitian at St. Vincent’s University Hospital in Dublin, where she has led specialist dietetic care for patients since 2011. She is also an Adjunct Associate Professor at University College Dublin, conducting research on nutrition in cancer care. Her work focuses on improving outcomes for people with pancreatic cancer through tailored nutritional support and clinical research, and she has been widely recognized for her contributions to oncology dietetics, leadership, and mentorship.

Image about a team member of the Cluster, Anne Fortune

07Nov

Dr. Anne Fortune: Leading Innovation in Haematology at Mater Hospital

Meet our team: Dr. Anne Fortune, Consultant Haematologist at Mater Misericordiae University Hospital, is a leading expert in blood cancer research and patient care. A graduate of NIUG, she has led numerous national an international trials in lymphoma, CLL and MDS, driving access to innovation treatments. As chair of Cancer Trials Ireland's Haematology and Lymphoma Subgroup, Dr. Fortune plays a key role in advancing collaborative, patient-focused research across Ireland.

$Dr. Jemma Buchalter: Advancing Cancer Trials and Patient Care in Ireland\n$ 24Oct

Dr. Jemma Buchalter: Advancing Cancer Trials and Patient Care in Ireland

Dr. Jemma Buchalter is a leading figure in oncology research, dedicated to transforming cancer care and clinical trials across Ireland. With a focus on innovation, collaboration, and patient-centered outcomes, Dr. Buchalter is advancing the development and delivery of cutting-edge treatments, ensuring that Irish patients have access to the latest breakthroughs in cancer therapy. Her work bridges science and compassion, driving meaningful progress in both research and real-world patient care.

06Oct

Strengthening Patient and Public Involvement: Reflections and Actions

As September ended and October began, we immersed ourselves in Patient and Public Involvement through the HSE Public and Partnership Conference and the PPI Ignite Festival. These events brought together patients, carers, healthcare professionals, and policy-makers, offering inspiration, lessons, and encouragement on the journey toward authentic partnership in clinical care and research. At UCD Cancer Trials Cluster, we were proud to contribute through our work to these two events and to strengthening patient and public involvement in cancer research and care.

15Sep

FAIR Trials: Facilitating Access, Inclusion and Representation in Oncology Clinical Trials

We are happy to announce the start of a new research project, FAIR Trials: Facilitating Access, Inclusion and Representation in Oncology Trials.
This project aims to enhance a diverse representation in cancer clinical trials and therefore improve patient care across all patient demographics. We will deploy quantitative and qualitative methods to explore and analyse the social, cultural, economic and psychological barriers that hinder participation in cancer clinical trials and will propose a plan of action to overcome these barriers.

09Sep

At the Front of Innovation in Blood Cancers

Dr. Liam Smyth, Consultant Haematologist at St. Vincent’s University Hospital (SVUH), is at the forefront of advancing blood cancer treatment through his work in malignant haematology and immunotherapy. Dr. Smyth supports the growing haematology clinical trials program at SVUH. In partnership with the UCD Cancer Trials Cluster, the hospital’s Haematology Research Group has increased exponentially its clinical research portfolio in the last year. Current trials focus on innovative therapies, aligning with global efforts to improve outcomes for patients with haematological malignancies.

28Aug

The Living Stories Behind Cancer Research

You're Invited: The Living Stories Behind Cancer Research
The UCD Cancer Trials Cluster and St. Vincent’s UCD Cancer Centre, in collaboration with The Patient Voice in Cancer Research, UCD PPI Ignite Network, and the Irish Cancer Society, are delighted to host:

The Living Stories Behind Cancer Research
Tuesday, October 7
5:30 PM – 7:00 PM
Museum of Literature Ireland (MoLI), Old Physics Room

Banner for Global Clinical Trial guidelines

04Aug

Global Clinical Trial Guidelines Modernised with ICH GCP E6(R3)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has officially released the long-awaited revision to its Good Clinical Practice (GCP) guidelines: ICH GCP E6(R3).

In collaboration with the UCD Clinical Research Centre, we’ve co-authored a summary of the newly updated global clinical trial guidelines – ICH GCP E6(R3).

Image featuring a dialogue between a scientist and a patient

23Jun

Science meets Lived Experience: Patients Shaping Health Research in Ireland

In this interview, we speak with Jim, a retired project manager from County Kildare who is now a dedicated Public and Patient Involvement (PPI) contributor. With a long-standing commitment to volunteering, he first encountered PPI through a hospital poster in 2020. Since then, he has become an active voice in a wide range of research initiatives, from cancer studies to national health data projects. Here, he shares how his personal experiences have shaped his involvement, the impact he’s made, and why he believes PPI is essential to research.

09Jun

UCD Festival 2025

Last Saturday, 7th June, we took part in the UCD Festival 2025, a lively and inclusive celebration of learning, culture, and community spirit right here on campus. The festival attracted over 18,000 visitors and featured more than 130 free events spread across eight themed zones, offering something for everyone, no matter their age or interests. We were delighted to welcome so many people to the stand at the Clinical Research Centre.

Click here to view all news and events

Latest Trial News

14Oct

Breast Cancer Research Study: CAMBRIA-2

This study is for patients who have already had surgery and finished their first treatments, such as chemotherapy and radiotherapy, if needed. Researchers want to see if a drug, called camizestrant (AZD9833), can do a better job at preventing breast cancer from coming back compared to the current standard of care anti-hormone treatments called aromatase inhibitors.
You can join the CAMBRIA-2 study at the Mater Misericordiae University Hospital (MMUH), Mater Private Hospital (MPH).
and St Vincent’s University Hospital (SVUH).

22Sep

MK-2870: Exploring a New Therapy for Women with Recurrent Cervical Cancer

A new international clinical trial,MK-2870, is now open for women with recurrent or metastatic cervical cancer who have already received standard treatment. This study is exploring a promising new treatment called sacituzumab tirumotecan (MK-2870) to see if it can help women live longer and feel better compared to current second-line therapies.
Women in Ireland can participate in this trial at Mater Misericordiae University Hospital (MMUH) in Dublin.

29Apr

Upcoming Clinical Trials in May 2025

Helping you access tomorrow’s treatments today
Be part of cutting-edge cancer research happening at UCD Cancer Trial Cluster. Whether you're newly diagnosed or exploring further treatment options, our upcoming trials offer hope through innovation — with access to the latest therapies for gynaecological, breast, lung, and other cancers.
Explore the trials below to see if one could be right for you.

Image featuring Oasis 4 Trial Results Simple

16Jun

Results from Phase III OASIS-4 Trial

Results from Phase III OASIS-4 Trial shows that elinzanetant significantly decreases the occurrence of moderate to severe vasomotor symptoms linked to endocrine therapy in breast cancer patients.
Elinzanetant offers a new, targeted approach, specifically addressing the needs of women who experience menopause-like symptoms due to cancer treatment. With leading Irish hospitals actively involved in this international trial, patients in Ireland are contributing to, and standing to benefit from, meaningful advances in cancer care and quality of life.

22Jul

Destiny 15: Study on People with Advanced Breast Cancer

Ireland is now part of a major international study called DESTINY‑Breast15, which brings new treatment options to people with types of breast cancer that until recently had very few targeted treatments available.
This trial is part of a new wave of research focused on breast cancers with little or no HER2 protein.

A graphic of a megaphone next to text reading 'destiny-12 trial results'

16Sep

DESTINY-12 Results

The first results of DESTINY-12 have been published, examining the effectiveness of trastuzumab deruxtecan (T-DXd) in people with advanced HER2-positive breast cancer, particularly in patients with brain metastases.

A navy thumbnail against a yellow background. The text reads: New studies ASTER-ANT-007 and POST. To treat venous thromboembolism and explore the languge of cancer.

08Dec

Venous thromboembolism & Survivorship Studies

Two new studies open exploring treatments for venous thromboembolism and the language used to describe people with cancer.

Speech bubble with the text: New Trials. LATIFY & MOUNTAINEERING-03. To treat metastatic colorectal cancer and non-small cell lung cancer.

06Nov

New Trials - LATIFY and MOUNTAINEER-03

Two new trials for people with metastatic colorectal cancer and non-small cell lung cancer.

Exterior photo of Herbert Park Hotel. The modern building is against a clear sky and there is a tree at the foreground of the photo

27Sep

Symposium on Translational Research in Oncology

The 16th International Symposium on Translational Research in Oncology will take place 27th-29th September 2023.

Click here to view all news and events

Contact the UCD Cancer Trials Cluster

UCD Clinical Research Centre, St Vincent's University Hospital, Elm Park, Dublin 4

E: cancertrials@ucd.ie

Explore UCD

About UCD

Students

Research & Innovation

Colleges

Engage

Key Services

On This Page